Nat Nanotechnol:绿茶主要成分或可用作抗癌蛋白载体

2014-10-23 张笑 中国科学报

绿茶中的一种主要成分能够作为抗癌蛋白载体,用来合成一种稳定、有效的治疗用纳米复合物。在线发表于《自然-纳米技术》上的这项发现或有助于建立更好的药物投递系统。 一些癌症治疗方法的效果依赖于药剂中的治疗成分和将药物投递至肿瘤位置的载体。设计药物载体时,有几个因素必须考虑:首先,其必须具有特定性,这样才能针对肿瘤而不伤及其他组织;其次,药物与载体的配比也很重要,因为如果身体无法代谢载体的话

绿茶中的一种主要成分能够作为抗癌蛋白载体,用来合成一种稳定、有效的治疗用纳米复合物。在线发表于《自然-纳米技术》上的这项发现或有助于建立更好的药物投递系统。

一些癌症治疗方法的效果依赖于药剂中的治疗成分和将药物投递至肿瘤位置的载体。设计药物载体时,有几个因素必须考虑:首先,其必须具有特定性,这样才能针对肿瘤而不伤及其他组织;其次,药物与载体的配比也很重要,因为如果身体无法代谢载体的话,载体剂量过高可能导致中毒;再者,如果身体对药物的排斥、消耗过快,会让药物失效。

Joo Eun Chung等人利用表没食子儿茶素没食子酸酯(简称EGCG)这一绿茶中含量丰富的成分制成抗癌蛋白赫赛汀的载体。相比其他载体,EGCG的优点在于它自身也具有抗癌作用。研究人员将含有EGCG和赫赛汀的纳米合成物注入小鼠体内后发现,与单独注射赫赛汀相比而言,这种合成物显示出了更好的肿瘤选择性和肿瘤生长减缓效果,其在血液内的留存时间也变长--同时也增强了其药效。

原始出处:

Chung JE1, Tan S1, Gao SJ1, Yongvongsoontorn N1, Kim SH2, Lee JH2, Choi HS2, Yano H3, Zhuo L1, Kurisawa M1, Ying JY1.Self-assembled micellar nanocomplexes comprising green tea catechin derivatives and protein drugs for cancer therapy.Nat Nanotechnol. 2014 Oct 5. doi: 10.1038/nnano.2014.208. [Epub ahead of print]

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1811583, encodeId=fe7f1811583d5, content=<a href='/topic/show?id=5eb488e59c2' target=_blank style='color:#2F92EE;'>#蛋白载体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=88759, encryptionId=5eb488e59c2, topicName=蛋白载体)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b63894, createdName=minlingfeng, createdTime=Sat Jul 25 04:11:00 CST 2015, time=2015-07-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1652114, encodeId=d6d416521140f, content=<a href='/topic/show?id=13d01e24509' target=_blank style='color:#2F92EE;'>#TEC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17245, encryptionId=13d01e24509, topicName=TEC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=852f24292001, createdName=shock_melon, createdTime=Tue Sep 15 08:11:00 CST 2015, time=2015-09-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1880324, encodeId=04af188032466, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Tue Mar 03 18:11:00 CST 2015, time=2015-03-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1645417, encodeId=2ba2164541e20, content=<a href='/topic/show?id=db329364360' target=_blank style='color:#2F92EE;'>#载体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93643, encryptionId=db329364360, topicName=载体)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=58cb23213384, createdName=mei539, createdTime=Sun Sep 27 19:11:00 CST 2015, time=2015-09-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1402276, encodeId=96fe14022e6c3, content=<a href='/topic/show?id=862e8e196a1' target=_blank style='color:#2F92EE;'>#茶#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87196, encryptionId=862e8e196a1, topicName=茶)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/eTyQ1TyLVfyaGrflWSd1Jw4u1F68ibicmN32DE38FjEW3zTIKeFeaMUAQsjyqaL4QZ3lRibFIzziacMz9niceznOTTw/132, createdBy=03082405249, createdName=hbwxf, createdTime=Sat Oct 25 00:11:00 CST 2014, time=2014-10-25, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1811583, encodeId=fe7f1811583d5, content=<a href='/topic/show?id=5eb488e59c2' target=_blank style='color:#2F92EE;'>#蛋白载体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=88759, encryptionId=5eb488e59c2, topicName=蛋白载体)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b63894, createdName=minlingfeng, createdTime=Sat Jul 25 04:11:00 CST 2015, time=2015-07-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1652114, encodeId=d6d416521140f, content=<a href='/topic/show?id=13d01e24509' target=_blank style='color:#2F92EE;'>#TEC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17245, encryptionId=13d01e24509, topicName=TEC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=852f24292001, createdName=shock_melon, createdTime=Tue Sep 15 08:11:00 CST 2015, time=2015-09-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1880324, encodeId=04af188032466, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Tue Mar 03 18:11:00 CST 2015, time=2015-03-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1645417, encodeId=2ba2164541e20, content=<a href='/topic/show?id=db329364360' target=_blank style='color:#2F92EE;'>#载体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93643, encryptionId=db329364360, topicName=载体)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=58cb23213384, createdName=mei539, createdTime=Sun Sep 27 19:11:00 CST 2015, time=2015-09-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1402276, encodeId=96fe14022e6c3, content=<a href='/topic/show?id=862e8e196a1' target=_blank style='color:#2F92EE;'>#茶#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87196, encryptionId=862e8e196a1, topicName=茶)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/eTyQ1TyLVfyaGrflWSd1Jw4u1F68ibicmN32DE38FjEW3zTIKeFeaMUAQsjyqaL4QZ3lRibFIzziacMz9niceznOTTw/132, createdBy=03082405249, createdName=hbwxf, createdTime=Sat Oct 25 00:11:00 CST 2014, time=2014-10-25, status=1, ipAttribution=)]
    2015-09-15 shock_melon
  3. [GetPortalCommentsPageByObjectIdResponse(id=1811583, encodeId=fe7f1811583d5, content=<a href='/topic/show?id=5eb488e59c2' target=_blank style='color:#2F92EE;'>#蛋白载体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=88759, encryptionId=5eb488e59c2, topicName=蛋白载体)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b63894, createdName=minlingfeng, createdTime=Sat Jul 25 04:11:00 CST 2015, time=2015-07-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1652114, encodeId=d6d416521140f, content=<a href='/topic/show?id=13d01e24509' target=_blank style='color:#2F92EE;'>#TEC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17245, encryptionId=13d01e24509, topicName=TEC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=852f24292001, createdName=shock_melon, createdTime=Tue Sep 15 08:11:00 CST 2015, time=2015-09-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1880324, encodeId=04af188032466, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Tue Mar 03 18:11:00 CST 2015, time=2015-03-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1645417, encodeId=2ba2164541e20, content=<a href='/topic/show?id=db329364360' target=_blank style='color:#2F92EE;'>#载体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93643, encryptionId=db329364360, topicName=载体)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=58cb23213384, createdName=mei539, createdTime=Sun Sep 27 19:11:00 CST 2015, time=2015-09-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1402276, encodeId=96fe14022e6c3, content=<a href='/topic/show?id=862e8e196a1' target=_blank style='color:#2F92EE;'>#茶#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87196, encryptionId=862e8e196a1, topicName=茶)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/eTyQ1TyLVfyaGrflWSd1Jw4u1F68ibicmN32DE38FjEW3zTIKeFeaMUAQsjyqaL4QZ3lRibFIzziacMz9niceznOTTw/132, createdBy=03082405249, createdName=hbwxf, createdTime=Sat Oct 25 00:11:00 CST 2014, time=2014-10-25, status=1, ipAttribution=)]
    2015-03-03 liye789132251
  4. [GetPortalCommentsPageByObjectIdResponse(id=1811583, encodeId=fe7f1811583d5, content=<a href='/topic/show?id=5eb488e59c2' target=_blank style='color:#2F92EE;'>#蛋白载体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=88759, encryptionId=5eb488e59c2, topicName=蛋白载体)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b63894, createdName=minlingfeng, createdTime=Sat Jul 25 04:11:00 CST 2015, time=2015-07-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1652114, encodeId=d6d416521140f, content=<a href='/topic/show?id=13d01e24509' target=_blank style='color:#2F92EE;'>#TEC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17245, encryptionId=13d01e24509, topicName=TEC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=852f24292001, createdName=shock_melon, createdTime=Tue Sep 15 08:11:00 CST 2015, time=2015-09-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1880324, encodeId=04af188032466, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Tue Mar 03 18:11:00 CST 2015, time=2015-03-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1645417, encodeId=2ba2164541e20, content=<a href='/topic/show?id=db329364360' target=_blank style='color:#2F92EE;'>#载体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93643, encryptionId=db329364360, topicName=载体)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=58cb23213384, createdName=mei539, createdTime=Sun Sep 27 19:11:00 CST 2015, time=2015-09-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1402276, encodeId=96fe14022e6c3, content=<a href='/topic/show?id=862e8e196a1' target=_blank style='color:#2F92EE;'>#茶#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87196, encryptionId=862e8e196a1, topicName=茶)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/eTyQ1TyLVfyaGrflWSd1Jw4u1F68ibicmN32DE38FjEW3zTIKeFeaMUAQsjyqaL4QZ3lRibFIzziacMz9niceznOTTw/132, createdBy=03082405249, createdName=hbwxf, createdTime=Sat Oct 25 00:11:00 CST 2014, time=2014-10-25, status=1, ipAttribution=)]
    2015-09-27 mei539
  5. [GetPortalCommentsPageByObjectIdResponse(id=1811583, encodeId=fe7f1811583d5, content=<a href='/topic/show?id=5eb488e59c2' target=_blank style='color:#2F92EE;'>#蛋白载体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=88759, encryptionId=5eb488e59c2, topicName=蛋白载体)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b63894, createdName=minlingfeng, createdTime=Sat Jul 25 04:11:00 CST 2015, time=2015-07-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1652114, encodeId=d6d416521140f, content=<a href='/topic/show?id=13d01e24509' target=_blank style='color:#2F92EE;'>#TEC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17245, encryptionId=13d01e24509, topicName=TEC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=852f24292001, createdName=shock_melon, createdTime=Tue Sep 15 08:11:00 CST 2015, time=2015-09-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1880324, encodeId=04af188032466, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Tue Mar 03 18:11:00 CST 2015, time=2015-03-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1645417, encodeId=2ba2164541e20, content=<a href='/topic/show?id=db329364360' target=_blank style='color:#2F92EE;'>#载体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93643, encryptionId=db329364360, topicName=载体)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=58cb23213384, createdName=mei539, createdTime=Sun Sep 27 19:11:00 CST 2015, time=2015-09-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1402276, encodeId=96fe14022e6c3, content=<a href='/topic/show?id=862e8e196a1' target=_blank style='color:#2F92EE;'>#茶#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87196, encryptionId=862e8e196a1, topicName=茶)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/eTyQ1TyLVfyaGrflWSd1Jw4u1F68ibicmN32DE38FjEW3zTIKeFeaMUAQsjyqaL4QZ3lRibFIzziacMz9niceznOTTw/132, createdBy=03082405249, createdName=hbwxf, createdTime=Sat Oct 25 00:11:00 CST 2014, time=2014-10-25, status=1, ipAttribution=)]
    2014-10-25 hbwxf

相关资讯

中国晚期胃癌靶向药物上市

  上海罗氏制药日前宣布,其抗人表皮生长因子受体2(HER2)药物——赫赛汀(曲妥珠单抗)继成功用于HER2阳性乳腺癌治疗后,继续在胃癌治疗领域实现重大突破。   “HER2是预测今后胃癌病情发展情况的一个重要预后因子,胃癌患者在接受治疗前必须明确HER2状态,以获得更具针对性的个体化治疗方案。”中国抗癌协会临床肿瘤学协作专业委员会(CSCO)主任委员、中国人民解放军八一医院副院长秦叔逵教授指出

Mol Cell:癌症细胞对赫赛汀产生耐药的原因

乳腺癌疗法,如以HER2为靶点赫赛汀疗法给增加了许多女性的开支;然而近一半的乳腺癌从一开始治疗就对赫赛汀产生了耐药。如今来自密歇根大学癌症研究中心的科学家发现了癌症细胞为何如此耐药的原因,研究者表示,癌细胞完全是通过另外一种路径来作用的,其中一种涉及炎症,这就为癌细胞不依赖HER2为靶点提供了基础。 这种途径涉及一种蛋白质名为白介素-6(IL-6),研究人员在小鼠中进行实验,解释了一种药物可以阻